TREATMENT OF myofascial and neuropathic pain SYNTOMATHOLOGY MedDRA version: 6.1 Level: PT Classification code 10029328
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: AGE BETWEEN 20 - 75 YEARS PTS WITH myofascial and neuropathic pain, AS THE CLINICAL AND DIAGNOSTIC CRITERIA SUGGESTED BY IASP Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - PATIENTS WITH OTHER PAIN SITUATION, ALSO CONCOMITANT TO myofascial and neuropathic pain - PREGNANCY
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: EVALUATION OF TROPISETRON ACTIVITY AT THE DOSE OF 5MG/DIE ON myofascial and neuropathic pain;Secondary Objective: EVALUATION OF TROPISETRON ACTIVITY AT THE DOSE OF 5MG/DIE CONCERNING TO: - QUALITY OF LIFE - MODIFICATION OF myofascial and neuropathic pain INDEX;Primary end point(s): EVALUATION OF PATIENTS NUMBER WHICH, AFTER 5 WEEKS FROM THE LOCAL TREATMENT BEGINNING WITH TROPISETRON 0,5 MG PER PUNTO TRIGGER, WILL HAVE A DECREASING OF, AT LEAST, 33/100 UNITS OF FIQ | — |
Countries
Italy